Avadel Common Stock vs Long Term Debt Analysis

AVDL Stock

USD 15.49 0.45 2.82%

Avadel Pharmaceuticals financial indicator trend analysis is way more than just evaluating Avadel Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Avadel Pharmaceuticals is a good investment. Please check the relationship between Avadel Pharmaceuticals Common Stock and its Long Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

Common Stock vs Long Term Debt

Common Stock vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Avadel Pharmaceuticals Common Stock account and Long Term Debt. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Avadel Pharmaceuticals' Common Stock and Long Term Debt is -0.4. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Avadel Pharmaceuticals PLC, assuming nothing else is changed. The correlation between historical values of Avadel Pharmaceuticals' Common Stock and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Avadel Pharmaceuticals PLC are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Common Stock i.e., Avadel Pharmaceuticals' Common Stock and Long Term Debt go up and down completely randomly.

Correlation Coefficient

-0.4

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Common Stock

Long Term Debt

Long-term debt is a debt that Avadel Pharmaceuticals has held for over one year. Long-term debt appears on Avadel Pharmaceuticals PLC balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Avadel Pharmaceuticals PLC balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most indicators from Avadel Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Avadel Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

At this time, Avadel Pharmaceuticals' Selling General Administrative is quite stable compared to the past year. Issuance Of Capital Stock is expected to rise to about 153.4 M this year, although the value of Discontinued Operations will most likely fall to about 4.2 M.

	2021	2022	2023	2024 (projected)
Interest Expense	9.9M	12.3M	9.9M	10.4M
Depreciation And Amortization	979K	4.8M	1.8M	1.7M

Interest Expense Depreciation And Amortization

Avadel Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock Total Equity	Common Stock
Total Assets		0.21	0.47	0.36	0.71	-0.46	-0.01	-0.42	0.42	0.53	0.34	0.21	0.87	0.13	0.55	0.7	0.19	0.65	0.52	0.78	-0.31	0.91	-0.21	-0.01	-0.31	-0.31
Short Long Term Debt Total	0.21		-0.44	-0.06	-0.13	-0.16	0.9	-0.32	-0.1	0.32	-0.19	-0.01	0.3	-0.3	0.21	0.47	-0.25	0.38	0.23	0.42	-0.12	0.3	0.44	-0.45	-0.2	-0.21
Other Current Liab	0.47	-0.44		0.78	0.19	-0.23	-0.44	0.02	0.35	-0.04	0.45	-0.1	0.25	0.56	0.08	0.17	0.39	-0.13	0.04	0.48	-0.33	0.27	-0.17	0.6	-0.13	-0.14
Total Current Liabilities	0.36	-0.06	0.78		-0.11	-0.33	-0.14	-0.14	0.55	0.17	0.32	-0.39	0.2	0.43	0.14	0.18	0.38	-0.26	0.1	0.6	-0.44	0.2	0.42	0.5	0.07	0.07
Total Stockholder Equity	0.71	-0.13	0.19	-0.11		-0.29	-0.33	-0.15	0.12	0.44	0.2	0.33	0.67	-0.2	0.38	0.19	0.06	0.76	0.36	0.1	-0.13	0.7	-0.41	0.05	-0.13	-0.12
Property Plant And Equipment Net	-0.46	-0.16	-0.23	-0.33	-0.29		0.12	0.39	-0.47	-0.62	0.0	0.11	-0.62	0.4	-0.46	-0.38	-0.19	-0.31	-0.46	-0.39	0.82	-0.57	-0.05	0.39	0.32	0.31
Net Debt	-0.01	0.9	-0.44	-0.14	-0.33	0.12		-0.14	-0.3	-0.12	-0.09	0.16	-0.04	-0.08	-0.02	0.34	-0.19	0.15	0.03	0.28	0.13	-0.01	0.33	-0.28	-0.19	-0.21
Retained Earnings	-0.42	-0.32	0.02	-0.14	-0.15	0.39	-0.14		-0.54	-0.39	-0.51	0.21	-0.37	0.03	-0.96	-0.7	-0.55	-0.17	-0.97	-0.45	-0.05	-0.36	-0.1	0.44	0.46	0.42
Accounts Payable	0.42	-0.1	0.35	0.55	0.12	-0.47	-0.3	-0.54		0.43	0.34	-0.24	0.32	0.12	0.56	0.32	0.49	-0.05	0.5	0.49	-0.31	0.3	0.19	-0.02	0.12	0.15
Cash	0.53	0.32	-0.04	0.17	0.44	-0.62	-0.12	-0.39	0.43		-0.28	-0.39	0.78	-0.5	0.5	0.33	-0.2	0.56	0.45	0.35	-0.58	0.73	0.29	-0.39	-0.02	-0.02
Non Current Assets Total	0.34	-0.19	0.45	0.32	0.2	0.0	-0.09	-0.51	0.34	-0.28		0.18	-0.06	0.59	0.53	0.41	0.8	-0.11	0.54	0.29	0.33	0.01	-0.21	0.34	-0.25	-0.21
Non Currrent Assets Other	0.21	-0.01	-0.1	-0.39	0.33	0.11	0.16	0.21	-0.24	-0.39	0.18		0.07	0.12	-0.14	0.19	0.04	0.4	-0.11	0.0	0.26	0.14	-0.67	0.01	-0.1	-0.1
Cash And Short Term Investments	0.87	0.3	0.25	0.2	0.67	-0.62	-0.04	-0.37	0.32	0.78	-0.06	0.07		-0.24	0.51	0.62	-0.06	0.75	0.48	0.63	-0.52	0.99	-0.13	-0.29	-0.27	-0.28
Net Receivables	0.13	-0.3	0.56	0.43	-0.2	0.4	-0.08	0.03	0.12	-0.5	0.59	0.12	-0.24		-0.09	0.21	0.48	-0.43	-0.08	0.35	0.4	-0.17	-0.12	0.49	0.07	0.08
Common Stock Shares Outstanding	0.55	0.21	0.08	0.14	0.38	-0.46	-0.02	-0.96	0.56	0.5	0.53	-0.14	0.51	-0.09		0.69	0.53	0.35	0.99	0.43	-0.04	0.51	-0.02	-0.36	-0.44	-0.4
Non Current Liabilities Total	0.7	0.47	0.17	0.18	0.19	-0.38	0.34	-0.7	0.32	0.33	0.41	0.19	0.62	0.21	0.69		0.32	0.4	0.7	0.81	-0.09	0.65	-0.18	-0.4	-0.51	-0.5
Inventory	0.19	-0.25	0.39	0.38	0.06	-0.19	-0.19	-0.55	0.49	-0.2	0.8	0.04	-0.06	0.48	0.53	0.32		-0.33	0.56	0.21	0.17	-0.03	-0.04	0.09	-0.02	0.03
Other Current Assets	0.65	0.38	-0.13	-0.26	0.76	-0.31	0.15	-0.17	-0.05	0.56	-0.11	0.4	0.75	-0.43	0.35	0.4	-0.33		0.32	0.24	-0.22	0.78	-0.3	-0.22	-0.32	-0.33
Other Stockholder Equity	0.52	0.23	0.04	0.1	0.36	-0.46	0.03	-0.97	0.5	0.45	0.54	-0.11	0.48	-0.08	0.99	0.7	0.56	0.32		0.41	0.0	0.48	-0.03	-0.41	-0.48	-0.44
Total Liab	0.78	0.42	0.48	0.6	0.1	-0.39	0.28	-0.45	0.49	0.35	0.29	0.0	0.63	0.35	0.43	0.81	0.21	0.24	0.41		-0.32	0.66	0.07	-0.06	-0.32	-0.32
Property Plant And Equipment Gross	-0.31	-0.12	-0.33	-0.44	-0.13	0.82	0.13	-0.05	-0.31	-0.58	0.33	0.26	-0.52	0.4	-0.04	-0.09	0.17	-0.22	0.0	-0.32		-0.46	-0.21	0.14	0.07	0.09
Total Current Assets	0.91	0.3	0.27	0.2	0.7	-0.57	-0.01	-0.36	0.3	0.73	0.01	0.14	0.99	-0.17	0.51	0.65	-0.03	0.78	0.48	0.66	-0.46		-0.17	-0.25	-0.28	-0.28
Short Term Debt	-0.21	0.44	-0.17	0.42	-0.41	-0.05	0.33	-0.1	0.19	0.29	-0.21	-0.67	-0.13	-0.12	-0.02	-0.18	-0.04	-0.3	-0.03	0.07	-0.21	-0.17		0.02	0.37	0.37
Intangible Assets	-0.01	-0.45	0.6	0.5	0.05	0.39	-0.28	0.44	-0.02	-0.39	0.34	0.01	-0.29	0.49	-0.36	-0.4	0.09	-0.22	-0.41	-0.06	0.14	-0.25	0.02		0.26	0.24
Common Stock Total Equity	-0.31	-0.2	-0.13	0.07	-0.13	0.32	-0.19	0.46	0.12	-0.02	-0.25	-0.1	-0.27	0.07	-0.44	-0.51	-0.02	-0.32	-0.48	-0.32	0.07	-0.28	0.37	0.26		1.0
Common Stock	-0.31	-0.21	-0.14	0.07	-0.12	0.31	-0.21	0.42	0.15	-0.02	-0.21	-0.1	-0.28	0.08	-0.4	-0.5	0.03	-0.33	-0.44	-0.32	0.09	-0.28	0.37	0.24	1.0

Click cells to compare fundamentals

Avadel Pharmaceuticals Account Relationship Matchups

Avadel Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	151.4M	311.6M	247.3M	132.8M	261.1M	138.0M
Short Long Term Debt Total	124.7M	130.5M	145.0M	131.0M	35.4M	38.3M
Other Current Liab	3.9M	5.2M	5.3M	9.3M	24.5M	15.3M
Total Current Liabilities	36.0M	15.1M	21M	55.8M	36.9M	29.7M
Total Stockholder Equity	(29.2M)	162.3M	78.2M	(21.1M)	87.7M	47.1M
Property Plant And Equipment Net	4.2M	3.0M	2.9M	2.6M	3.2M	3.0M
Net Debt	114.9M	58.8M	94.3M	57.0M	4.2M	4.0M
Retained Earnings	(391.2M)	(384.2M)	(447.8M)	(585.2M)	(745.5M)	(708.2M)
Accounts Payable	6.1M	2.9M	7.7M	7.9M	11.4M	6.3M
Cash	9.8M	71.7M	50.7M	74.0M	31.2M	28.3M
Non Current Assets Total	69.1M	48.2M	54.8M	31.9M	126.9M	133.3M
Non Currrent Assets Other	39.3M	24.9M	33.8M	(60.0M)	10.2M	7.4M
Cash And Short Term Investments	64.2M	221.4M	157.2M	96.5M	105.1M	72.6M
Net Receivables	10.4M	3.3M	2.4M	2.2M	13.4M	9.7M
Common Stock Shares Outstanding	37.4M	54.9M	58.5M	60.1M	80.2M	84.2M
Liabilities And Stockholders Equity	151.4M	311.6M	247.3M	132.8M	261.1M	138.0M
Non Current Liabilities Total	144.7M	134.3M	148.0M	98.1M	136.5M	143.4M
Inventory	6.2M	4.8M	3.6M	0.0	10.4M	10.9M
Other Current Assets	4.3M	38.7M	32.8M	2.1M	5.3M	5.6M
Other Stockholder Equity	384.4M	566.9M	549.3M	589.8M	855.5M	898.2M
Total Liab	180.6M	149.4M	169.0M	153.9M	173.4M	90.9M
Property Plant And Equipment Gross	10.6M	8.2M	2.9M	2.6M	14.0M	12.4M
Total Current Assets	82.4M	263.5M	192.5M	100.8M	134.2M	91.1M
Accumulated Other Comprehensive Income	(22.8M)	(21.1M)	(23.9M)	(26.3M)	(23.2M)	(22.0M)
Short Term Debt	645K	474K	900K	38.6M	934K	887.3K
Common Stock Total Equity	427K	429K	583K	586K	527.4K	501.0K
Common Stock	429K	583K	586K	628K	898K	853.1K
Other Liab	20.6M	4.2M	3.9M	5.7M	6.6M	6.3M
Current Deferred Revenue	114K	25.4M	6.5M	7.2M	8.2M	4.2M
Other Assets	39.2M	28.4M	35.0M	12.6M	14.4M	10.2M
Long Term Debt	121.7M	128.2M	142.4M	91.6M	105.4M	110.6M
Property Plant Equipment	544K	359K	285K	2.6M	2.3M	2.2M
Short Term Investments	54.4M	149.7M	106.5M	22.5M	73.9M	64.8M
Net Tangible Assets	(48.5M)	145.4M	61.4M	(38.0M)	(43.7M)	(41.5M)
Retained Earnings Total Equity	(358.0M)	(391.2M)	(384.2M)	(447.8M)	(403.0M)	(423.1M)
Long Term Debt Total	115.7M	121.7M	128.2M	142.4M	163.8M	171.9M
Capital Surpluse	433.8M	434.4M	566.9M	549.3M	631.8M	491.4M

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Avadel Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

When determining whether Avadel Pharmaceuticals is a strong investment it is important to analyze Avadel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Avadel Pharmaceuticals' future performance. For an informed investment choice regarding Avadel Stock, refer to the following important reports:

How To Invest In Avadel

Details

Is Avadel Stock a good investment?

Details

What is Avadel Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

Note that the Avadel Pharmaceuticals information on this page should be used as a complementary analysis to other Avadel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Avadel Stock analysis

When running Avadel Pharmaceuticals' price analysis, check to measure Avadel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avadel Pharmaceuticals is operating at the current time. Most of Avadel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Avadel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avadel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Avadel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators

Is Avadel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.82)

Revenue Per Share

0.633

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.55)

Return On Equity

(7.80)

The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Avadel Common Stock vs Long Term Debt Analysis

Common Stock vs Long Term Debt

Common Stock vs Long Term Debt Correlation Analysis

Correlation Coefficient

Common Stock

Long Term Debt

Avadel Pharmaceuticals fundamental ratios Correlations

Avadel Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Avadel Pharmaceuticals fundamental ratios Accounts

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Complementary Tools for Avadel Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 0.99	Cash And Short Term Investments
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding
Total Current Assets	+ 0.91	Total Assets
Net Debt	+ 0.9	Short Long Term Debt Total
Cash And Short Term Investments	+ 0.87	Total Assets

Other Stockholder Equity	- 0.97	Retained Earnings
Common Stock Shares Outstanding	- 0.96	Retained Earnings
Non Current Liabilities Total	- 0.7	Retained Earnings
Short Term Debt	- 0.67	Non Currrent Assets Other
Cash And Short Term Investments	- 0.62	Property Plant And Equipment Net
Cash	- 0.62	Property Plant And Equipment Net